Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2019
The purpose of the study is to evaluate immunogenicity and safety of three different doses of candidate hexvalent vaccine in comparison to co‐administration of EupentaTM Inj. and Imovax® Polio in separate injections at four weeks after completion of three‐dose primary series at 6‐10‐14 weeks of age when administered to healthy infants and thereby to select the optimal dose of candidate vaccine
Epistemonikos ID: 8e8415794c9a5c0527bf3aa580741d72a65f686a
First added on: Nov 24, 2021